<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606682</url>
  </required_header>
  <id_info>
    <org_study_id>NPT200-11-001</org_study_id>
    <nct_id>NCT02606682</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of NPT200-11 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuropore Therapies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB S.A. - Pharma Sector</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuropore Therapies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and blood levels of orally
      administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be
      determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests</measure>
    <time_frame>Screening (28 days prior to dosing) through Day 7</time_frame>
    <description>Safety, as determined by the number of participants with adverse events related to treatment, the number of participants with clinically significant changes in blood pressure, heart rate and respiration, the number of participants with abnormal laboratory values, the number of participants with abnormal ECGs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To possibly determine the maximally tolerated dose (MTD) of orally administered NPT200-11 in healthy subjects.</measure>
    <time_frame>Screening (28 days prior to dosing) through Day 7 of MTD</time_frame>
    <description>The number of participants with unacceptable toxicities at each dose level will determine the maximally tolerated dose.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 1, Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 2, Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 3, Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 4, Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 5 ,Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 -Cohort 6, Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPT200-11 - Cohort 7, Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPT200-11</intervention_name>
    <description>Single doses of NPT200-11capsules, orally administered</description>
    <arm_group_label>NPT200-11 - Cohort 1, Dose 1</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 2, Dose 2</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 3, Dose 3</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 4, Dose 4</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 5 ,Dose 5</arm_group_label>
    <arm_group_label>NPT200-11 -Cohort 6, Dose 6</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 7, Dose 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single doses of microcrystalline cellulose capsules, orally administered</description>
    <arm_group_label>NPT200-11 - Cohort 1, Dose 1</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 2, Dose 2</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 3, Dose 3</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 4, Dose 4</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 5 ,Dose 5</arm_group_label>
    <arm_group_label>NPT200-11 -Cohort 6, Dose 6</arm_group_label>
    <arm_group_label>NPT200-11 - Cohort 7, Dose 7</arm_group_label>
    <other_name>Microcrystalline cellulose capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who meet all of the following inclusion criteria will be eligible to participate
        in this study:

          1. informed of, and willing and able to comply with, all of the protocol requirements and
             the investigational nature of the study, and have signed an informed consent form in
             accordance with institutional and regulatory guidelines;

          2. male or female adults between 18 and 55 years of age, inclusive;

          3. female subjects must be post-menopausal for at least 2 years or surgically sterile
             (hysterectomy, bilateral oophorectomy, tubal ligation);

          4. male subjects must be willing to use an adequate barrier method of contraception for
             the duration of the study and for 90 days after dosing and no sperm donations for the
             duration of the study and for 90 days after dosing. Male subjects who are surgically
             sterile need not employ a method of contraception;

          5. non-smokers for at least six months;

          6. BMI = 18 - 30 kg/m2, inclusive;

          7. in good health, in the judgment of the Principal Investigator, as determined by:

               -  medical history indicative of no serious or severe chronic conditions requiring
                  frequent medical intervention or continual pharmacologic management, and no
                  medical or social conditions that would potentially interfere with the subject's
                  ability to comply with the study visit schedule or the study assessments;

               -  no clinically significant abnormalities in body temperature, heart rate,
                  respiratory rate, blood pressure;

               -  no clinically significant abnormalities in the 12-lead electrocardiogram (ECG);

               -  no clinically significant abnormalities in clinical chemistry (ALT, AST, total
                  bilirubin must be at or below the upper limit of normal and eGFR must be above 90
                  mL/min), hematology (hemoglobin â‰¥ 12.0 g/dL), coagulation and urinalysis; lab
                  tests may be repeated, if necessary (details are provided in the attached flow
                  chart of study assessments).

          8. negative results on the following screening laboratory tests: urine drug screen, urine
             alcohol screen, serum pregnancy test, hepatitis B surface antigen, hepatitis C
             antibody, and human immunodeficiency virus antibody.

        Exclusion Criteria:

        Subjects who meet any of the following exclusion criteria will NOT be eligible to
        participate in this study:

          -  females of child bearing potential;

          -  history of a significant medical condition that may interfere with absorption,
             distribution or elimination of NPT200-11, or with the clinical and laboratory safety
             assessments in this study;

          -  history of drug hypersensitivity and disorders affecting respiratory function (e.g.,
             COPD, asthma) and cardiac disorders predisposing to cardiac adverse events;

          -  history of or current alcohol abuse and/or other drug addiction &lt; 2 years prior to
             screening, or a positive urine drug or alcohol screen (e.g., amphetamines,
             barbiturates, benzodiazepines, opiates, cannabinoids, alcohol and cocaine);

          -  positive for HBVsAg, HCV Ab, HIV Ab;

          -  12 lead ECG showing the following: having a corrected QTc interval &gt; 450 msec or &lt;320
             msec (Fridericia's correction);

          -  sustained sitting systolic blood pressure &gt; 140 or &lt; 90 mm Hg or sitting diastolic
             blood pressure &gt; 90 or &lt; 50 mm Hg at Screening or Day -1 (sentinel pair) or Day 1
             (remaining 6 subjects in the cohort), the average of the 2 assessments of BP taken at
             each visit will be used to exclude a subject;

          -  resting pulse rate at screening of &gt; 100 or &lt; 45;

          -  donated or lost &gt; 500 mL of blood &lt; 56 days prior to enrollment into this study;

          -  plasma donation within 7 days prior to enrollment into this study;

          -  active infection or febrile illness &lt; 14 days prior to the first dose of study
             medication;

          -  use of prescription or over-the-counter medications or herbal supplements â‰¤ 14 days
             prior to dosing and until completion of follow-up visit on Day 7;

          -  have participated in other clinical studies of a new chemical entity within 30 days
             prior to admission to the CRU.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Armas, M.D. CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, Inc</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Parkinson's Disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

